Illumina Inc. stock falls 1.24 percent, ending two-day winning streak

9 articles · Updated · MarketWatch · Apr 28

Shares closed at $126.92 on Tuesday, underperforming the S&P 500 and Dow Jones, with trading volume at 1.2 million, below the 50-day average.
Illumina's stock is now 18.39% below its 52-week high of $155.53, reached on January 22nd.
Despite the loss, Illumina outperformed some competitors, as Labcorp, Charles River Laboratories, and Quest Diagnostics also saw declines during the broadly negative market session.

Is Illumina's stock truly undervalued, or does its price reflect future competitive risks?

Can Illumina's new platforms fend off cheaper rivals threatening its market dominance?

With Q1 results due April 30, will Illumina meet its optimistic 2026 forecast?

How will Illumina navigate China's 'Unreliable Entities List' to reclaim market share?

How will shifting US and EU diagnostic regulations impact its clinical market expansion?

Will the SomaLogic acquisition and AI push be enough to drive future growth?